Table 1.
Protocol | Type of Trial | Protocol Tx | Setting | N |
---|---|---|---|---|
ECOG-1202 | Phase II | Chemotherapy | First Line | 10 |
ECOG-1298 | Phase II | Chemotherapy | First Line | 32 |
ECOG-2297 | Phase III | Chemotherapy | First Line | 321 |
ECOG-3292 | Phase II | Chemo/Immunoth. | First Line | 24 |
ECOG-3296 | Phase II | Chemotherapy | First Line | 36 |
NCCTG-0043 | Phase II | Chemo/Biologic | First Line | 48 |
NCCTG-014C | Randomized Phase II | Biologic | First Line | 42 |
NCCTG-014C | Randomized Phase II | Chemo/Biologic | First Line | 39 |
NCCTG-034A | Phase II | Chemo/Biologic | First Line | 79 |
NCCTG-894352 | Phase III | Chemotherapy | Either | 94 |
NCCTG-924352 | Phase II | Chemotherapy | Either | 46 |
NCCTG-964351 | Phase II | Chemotherapy | First Line | 13 |
NCCTG-984351 | Phase II | Chemotherapy | Either | 58 |
NCCTG-9942 | Phase II | Concurrent Chemo/RT | First Line | 46 |
RTOG-0020 | Randomized Phase II | Concurrent Chemo/RT | First Line | 91 |
RTOG-0411 | Phase II | Chemo/biologic/RT | First Line | 82 |
RTOG-9102 | Phase III | Concurrent Chemo/RT | First Line | 27 |
RTOG-9209 | Phase II | Concurrent Chemo/RT | First Line | 50 |
RTOG-9812 | Phase II | Concurrent Chemo/RT | Either | 109 |
SWOG-0107 | Phase II | Chemotherapy | First Line | 60 |
SWOG-0205 | Phase III | Chemotherapy | First Line | 347 |
SWOG-0205 | Phase III | Chemo/Biologic | First Line | 348 |
SWOG-8916 | Phase II | Chemotherapy | First Line | 25 |
SWOG-8933 | Phase II | Chemotherapy | First Line | 35 |
SWOG-9100 | Phase II | Chemo/Potentiator | First Line | 26 |
SWOG-9135 | Phase II | Chemotherapy | First Line | 39 |
SWOG-9413 | Phase II | Chemo/Immunoth. | First Line | 55 |
SWOG-9629 | Phase II | Chemo/Potentiator | First Line | 58 |
SWOG-9629 | Phase II | Chemo/Potentiator | Second Line or More | 48 |
SWOG-9924 | Phase II | Biologic | First Line | 53 |